{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:27:30Z","timestamp":1793636850611,"version":"4.5.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.thromres.2026.109854","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:00:25Z","timestamp":1790319625000},"page":"109854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Contemporary anticoagulation management in pulmonary embolism"],"prefix":"10.1016","volume":"266","author":[{"given":"Gary","family":"Hammerschlag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Yo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.thromres.2026.109854_bb0005","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jacc.2025.11.005","article-title":"2026 AHA\/ACC\/ACCP\/ACEP\/CHEST\/SCAI\/SHM\/SIR\/SVM\/SVN guideline for the evaluation and management of acute pulmonary embolism in adults","volume":"87","author":"Creager","year":"2026","journal-title":"JACC"},{"issue":"14","key":"10.1016\/j.thromres.2026.109854_bb0010","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"The EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.thromres.2026.109854_bb0015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2026.109854_bb0020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism","volume":"394","author":"Castellucci","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.thromres.2026.109854_bb0025","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMoa2509426","article-title":"Apixaban for extended treatment of provoked venous thromboembolism","volume":"393","author":"Piazza","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109854_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2026.109588","article-title":"Impact of enduring risk factors on efficacy and safety of extended anticoagulation for provoked venous thromboembolism: post-hoc analysis of the HI-PRO trial","volume":"258","author":"Pfeferman","year":"2026","journal-title":"Thromb. Res."},{"issue":"Supplement 2","key":"10.1016\/j.thromres.2026.109854_bb0035","doi-asserted-by":"crossref","first-page":"LBA-3","DOI":"10.1182\/blood-2024-212912","article-title":"Extended treatment of venous thromboembolism with reduced- vs full-dose direct oral anticoagulants in patients at high risk of recurrence","volume":"144","author":"Couturaud","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109854_bb0040","series-title":"ISTH 2025 Congress","article-title":"Extended reduced vs full-dose oral anticoagulant after venous thromboembolism in obese patients","author":"Couturaud","year":"2025"},{"issue":"13","key":"10.1016\/j.thromres.2026.109854_bb0045","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2026.109854_bb0050","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of Rivaroxaban in AntiPhospholipid syndrome (TRAPS): two-year outcomes after the study closure","volume":"19","author":"Pengo","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109854_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"22","key":"10.1016\/j.thromres.2026.109854_bb0060","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv."},{"issue":"23","key":"10.1016\/j.thromres.2026.109854_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018917","article-title":"Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study","volume":"9","author":"Campello","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"11","key":"10.1016\/j.thromres.2026.109854_bb0070","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1016\/j.jtha.2024.08.006","article-title":"The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia","volume":"22","author":"Kovac","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"17","key":"10.1016\/j.thromres.2026.109854_bb0075","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.thromres.2026.109854_bb0080","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.thromres.2026.109854_bb0085","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjmed.2023.01.010","article-title":"Direct oral anticoagulants in obese patients with venous thromboembolism: results of an expert consensus panel","volume":"136","author":"Rosovsky","year":"2023","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2026.109854_bb0090","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"22","key":"10.1016\/j.thromres.2026.109854_bb0095","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"Bates","year":"2018","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.thromres.2026.109854_bb0100","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1213\/ANE.0000000000002530","article-title":"The Society for Obstetric Anesthesia and Perinatology consensus statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants","volume":"126","author":"Leffert","year":"2018","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.thromres.2026.109854_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2017.03.013","article-title":"Oral contraception and menstrual bleeding during treatment of venous thromboembolism: expert opinion versus current practice","volume":"153","author":"Klok","year":"2017","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2026.109854_bb0110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.thromres.2026.109854_bb0115","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1056\/NEJM199506223322501","article-title":"A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism","volume":"332","author":"Schulman","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2026.109854_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103447","article-title":"Risk of venous thromboembolism in autoimmune diseases: a comprehensive review","volume":"22","author":"Menichelli","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"10480","key":"10.1016\/j.thromres.2026.109854_bb0125","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.thromres.2026.109854_bb0130","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.thromres.2026.109854_bb0135","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.thromres.2026.109854_bb0140","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.thromres.2026.109854_bb0145","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2026.109854_bb0150","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/hematology.2024000593","article-title":"Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing","volume":"2024","author":"Scheres","year":"2024","journal-title":"Hematology"},{"issue":"11","key":"10.1016\/j.thromres.2026.109854_bb0155","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2015-08-665927","article-title":"Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use","volume":"127","author":"Martinelli","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2026.109854_bb0160","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bjh.13534","article-title":"Clinical profile and recurrence rate in women with venous thromboembolism during combined hormonal contraceptive use: a prospective cohort study","volume":"172","author":"Van Vlijmen","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.thromres.2026.109854_bb0165","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.124.072758","article-title":"Rivaroxaban for 18 months versus 6 months in patients with cancer and acute low-risk pulmonary embolism: an open-label, multicenter, randomized clinical trial (ONCO PE trial)","volume":"151","author":"Yamashita","year":"2025","journal-title":"Circulation"},{"issue":"04","key":"10.1016\/j.thromres.2026.109854_bb0170","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1055\/a-1535-8726","article-title":"Deciding on treatment duration for unprovoked venous thromboembolism: what is important to patients?","volume":"122","author":"Van De Brug","year":"2022","journal-title":"Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:46:44Z","timestamp":1793634404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826002732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"alternative-id":["S0049384826002732"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109854","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary anticoagulation management in pulmonary embolism","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109854"}}